Joe Kiani Co-Founder Masimo Corp. The latest legal battle between Irvine-based medical device maker Masimo Corp. and Apple ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and ...

Masimo (MASI) delivered earnings and revenue surprises of 16.67% and 0.40%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 38%. Looking ahead, revenue ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Wells Fargo analyst Vik Chopra has assigned their bullish stance on MASI stock, giving a Buy rating yesterday. Vik Chopra has given his Buy ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

The tech giant also allegedly attempted to hire away key employees, including Cercacor’s former chief technology officer and ...

Penumbra and Inspire Medical Systems, providing valuable insights into their respective standings within the industry and their market positions and comparative performance. Masimo ranks at the ...

Masimo executives are back calling their consumer audio business Sound United, with a senior executive on a conference call ...

The medical technology company posted adjusted ... slightly above the $502.87 million estimate and up 11.5% YoY. However, Masimo's fourth-quarter revenue guidance of $581-611 million fell below ...